Latest Research And Development News

Page 8 of 87
EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.
Ada Torres
Ada Torres
10 Mar 2026
Janus Electric has locked in a $2.75 million R&D finance facility, strengthening its cash position to push forward with its zero-emission transport innovations. This strategic funding avoids shareholder dilution while supporting ongoing technology development.
Victor Sage
Victor Sage
9 Mar 2026
Island Pharmaceuticals has entered a pivotal research agreement with USAMRIID and the Geneva Foundation to accelerate FDA approval of Galidesivir for Marburg Virus Disease, leveraging top-tier US biodefense expertise.
Victor Sage
Victor Sage
4 Mar 2026
Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.
Ada Torres
Ada Torres
2 Mar 2026
Elixir Energy has reached a key milestone by drilling and casing the heel of its Lorelle-3H well in Queensland’s Taroom Trough, setting the stage for horizontal drilling aimed at unlocking commercial gas flow.
Maxwell Dee
Maxwell Dee
2 Mar 2026
FBR Limited reports a significant reduction in half-year losses alongside new robotic product launches, yet cash flow challenges raise questions about its financial sustainability.
Sophie Babbage
Sophie Babbage
27 Feb 2026
Merino & Co. Limited reported a 60.5% drop in revenue and a 28.2% increase in net loss for the half-year ending December 2025, reflecting a strategic investment phase aimed at future growth. The company is expanding production capacity and building inventory ahead of wholesale expansion, signaling a pivot towards revenue acceleration.
Victor Sage
Victor Sage
27 Feb 2026
Nanoveu Limited reported a dramatic revenue increase driven by its strategic acquisition of Embedded A.I. Systems, while losses widened as it invests heavily in semiconductor commercialisation. The company’s recent $7.5 million capital raise aims to fuel its next growth phase.
Sophie Babbage
Sophie Babbage
27 Feb 2026
PARKD Limited reported a 37% revenue decline to $3.88 million for H1 FY2026, driven by the winding down of its flagship Audi Centre Myaree project. The company posted a $1.03 million loss as it invests in East Coast growth and commissions a new prefabrication facility in Penrith, NSW.
Victor Sage
Victor Sage
27 Feb 2026
Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.
Ada Torres
Ada Torres
27 Feb 2026
Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.
Ada Torres
Ada Torres
27 Feb 2026
Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.
Ada Torres
Ada Torres
27 Feb 2026